Abstract 565
Background
Besides classical adenocarcinoma (AC), mucinous adenocarcinoma (MAC) and signet-ring cell carcinoma (SRCC) are less frequent subtypes of colorectal cancer, and their recent epidemiologic data are lacking. The current study was designed to explore the evolving epidemiology and prognosis of patients with colorectal MAC and SRCC, compared with AC.
Methods
The Surveillance, Epidemiology and End Results (SEER) registry database was adopted for patients with pathologically confirmed colorectal neoplasms as their first malignancy. Incidence and survival trends were estimated by age and histologic subtype. 5-year cancer specific survival (CSS) were evaluated for entire cohort, and compared in subgroups by age, grade and stage. Multivariate analysis of CSS was conducted for entire cohort.
Results
MAC incidence (per 100,000) declined slightly from 6.1 in 1975 to 5.6 in 2001, and fell to 2.5 in 2012 with an APC of -7.8% (95%CI=-8.8%–6.8%, P < 0.001), then reached a plateau. SRCC incidence gradually climbed from 0.1 in 1975 to 0.6 in 1999 with an APC of 8.3% (95%CI=7.2%-9.4%, P < 0.001) and went down to 0.4 in 2014 with an APC of -3.0% (95%CI=-5.0%–1.0%, P < 0.001). Among patients younger than age 50 years, MAC incidence decreased at an APC of -2.6% (95%CI: -3.6%–1.6%, P < 0.001), and SRCC remained stable, whereas AC incidence increased greatly at an APC of 1.9% (95%CI: 1.6%-2.2%, P < 0.001). Survival of both MAC and AC increased over time, while the survival of SRCC fluctuated without evident improvement. The 5-year CSS of SRCC was 31.3%, significantly lower than AC (66.6%) and MAC (60.4%). For AC and MAC Survival rate of patients aged below 50 years was superior to those aged 50 years or over through time, while in SRCC, after follow-up of approximately 20 months, the survival rate of younger patients dropped and became lower than older patients. Histologic subtype was an independent factor for CSS of CRC.
Conclusions
The incidence and survival of colorectal MAC and SRCC differs from traditional AC. Despite of the low incidence of SRCC, the survival is significantly worse than AC and MAC, especially for patients aged younger than 50 years. Further studies of the etiologies and treatment for rare subtypes of CRC are needed.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
NWGH.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
750 - HER2 positive rates in Invasive Lobular Breast Carcinoma : A study amongst 1,095 consecutive Asian patients
Presenter: Ga Jing Kee
Session: Poster display - Cocktail
Resources:
Abstract
1417 - CanAssist-breast -an immunohistochemistry based test for risk of recurrence prediction for early stage breast cancer patients: a cost-effective and accurate solution for Asia
Presenter: Manjiri Bakre
Session: Poster display - Cocktail
Resources:
Abstract
1468 - Topical silymarin administration for prevention of radiodermatitis in breast cancer patients: a randomized, double-blind, placebo-controlled clinical trial
Presenter: Sepideh Elyasi
Session: Poster display - Cocktail
Resources:
Abstract
873 - Comparison of interstitial brachytherapy with volumetric modulated arc therapy for tumour bed boost following breast conservative surgery
Presenter: Kannan Periasamy
Session: Poster display - Cocktail
Resources:
Abstract
1140 - Triple Negative Breast Cancer and Platinum-based Systemic Treatment: Meta-analysis and Systematic Review
Presenter: Jessa Gilda Pandy
Session: Poster display - Cocktail
Resources:
Abstract
168 - Longitudinal study on incidences of obesity and weight changes in Chinese patients with early-stage breast cancer
Presenter: Winnie Yeo
Session: Poster display - Cocktail
Resources:
Abstract
311 - Effect of combined CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome in breast cancer indicates endogenous and exogenous interplay
Presenter: Hanjing Xie
Session: Poster display - Cocktail
Resources:
Abstract
669 - A novel nipple aleolar complex involvement predictive index (NACPI) for indicating nipple sparing mastectomy in breast cancer
Presenter: Hirohito Seki
Session: Poster display - Cocktail
Resources:
Abstract
938 - Multicenter Trial for Safety and Toxicity of Nanoxel®M in Breast Cancer
Presenter: Tae Hyun Kim
Session: Poster display - Cocktail
Resources:
Abstract
1129 - Implication of PET-CT to improve negative predictive value for axillary lymph node metastasis in early breast cancer
Presenter: Oyeon Cho
Session: Poster display - Cocktail
Resources:
Abstract